{"id":516115,"date":"2021-07-22T02:03:05","date_gmt":"2021-07-22T06:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/"},"modified":"2021-07-22T02:03:05","modified_gmt":"2021-07-22T06:03:05","slug":"verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/","title":{"rendered":"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and RALEIGH, N.C., July  22, 2021  (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT \/ 1:30 p.m. BST to discuss these financial results and provide a corporate update.<\/p>\n<p align=\"justify\">To participate, please dial one of the following numbers and reference conference ID 8333487:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">+1-888-317-6003 for callers in the United States<\/li>\n<li style=\"text-align:justify\">+1-412-317-6061 for international callers<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast will be available on the Events and Presentations link on the Investors page of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZmGbXp3n14JfVnu8mN1y_x5Jp3gxQNx_V9cLqihBTGXxvPxBNrL0wYc8TT_GgbXCwJPscyUl_prdd9ARY-ZV1RUWvijkPttGcEMt_6D52zo=\" rel=\"nofollow noopener\" target=\"_blank\">www.veronapharma.com<\/a>, and the audio replay will be available for 90 days.<\/p>\n<p>For further information please contact:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:60%;width:60%;min-width:60%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Verona Pharma plc<\/strong>\n          <\/td>\n<td style=\"max-width:40%;width:40%;min-width:40%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">US Tel: +1-833-417-0262<br \/>UK Tel: +44 (0)203 283 4200<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Victoria Stewart, Director of Investor Relations and Communications<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <a href=\"mailto:info@veronapharma.com\" rel=\"nofollow noopener\" target=\"_blank\">info@veronapharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Argot Partners<\/strong><br \/>\n            <br \/>(US Investor Enquiries)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Tel: +1-212-600-1902<br \/><a href=\"mailto:verona@argotpartners.com\" rel=\"nofollow noopener\" target=\"_blank\">verona@argotpartners.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Kimberly Minarovich \/ Michael Barron<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Optimum Strategic Communications<\/strong><br \/>\n            <br \/>(International Media and European Investor Enquiries)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Tel: +44 (0)203 950 9144<br \/><a href=\"mailto:verona@optimumcomms.com\" rel=\"nofollow noopener\" target=\"_blank\">verona@optimumcomms.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Mary Clark \/ Karl Hard \/ Elakiya Rangarajah<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Verona Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma\u2019s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\u201cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\u201d) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (\u201cDPI\u201d) and pressurized metered-dose inhaler (\u201cpMDI\u201d). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZmGbXp3n14JfVnu8mN1y_5vnUgTgftgWLt-niTW4-XCrlyC0Y6HKSzLWQ6SG2YM2yZ8gvmw9fPCdIDXX9ZtBU7bl3dRhblPm7tnC7sd69YA=\" rel=\"nofollow noopener\" target=\"_blank\">www.veronapharma.com<\/a>.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/db7dfe57-0044-4dd5-ad3e-271743bae123\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT \/ 1:30 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and reference conference ID 8333487: +1-888-317-6003 for callers in the United States +1-412-317-6061 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company\u2019s website, www.veronapharma.com, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516115","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT \/ 1:30 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and reference conference ID 8333487: +1-888-317-6003 for callers in the United States +1-412-317-6061 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company\u2019s website, www.veronapharma.com, and &hellip; Continue reading &quot;Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T06:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update\",\"datePublished\":\"2021-07-22T06:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/\",\"name\":\"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=\",\"datePublished\":\"2021-07-22T06:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update - Market Newsdesk","og_description":"LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT \/ 1:30 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and reference conference ID 8333487: +1-888-317-6003 for callers in the United States +1-412-317-6061 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company\u2019s website, www.veronapharma.com, and &hellip; Continue reading \"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T06:03:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update","datePublished":"2021-07-22T06:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/","name":"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=","datePublished":"2021-07-22T06:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM0OSM0MzA3ODcxIzIwODQzNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-second-quarter-2021-financial-results-and-provide-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516115"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516115\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}